Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92643
UPID:
GPI8_HUMAN
Alternative names:
GPI8 homolog; Phosphatidylinositol-glycan biosynthesis class K protein
Alternative UPACC:
Q92643; B2R7K3; B4E2M3; O14822; Q5TG77
Background:
The GPI-anchor transamidase, also known as GPI8 homolog and Phosphatidylinositol-glycan biosynthesis class K protein, plays a crucial role in the post-translational modification of proteins. It is essential for the attachment of GPI (glycosylphosphatidylinositol) anchors to proteins in the endoplasmic reticulum. This process is vital for the proper localization and function of GPI-anchored proteins.
Therapeutic significance:
The GPI-anchor transamidase is linked to a neurodevelopmental disorder characterized by hypotonia, cerebellar atrophy, and potential seizures. Understanding the role of GPI-anchor transamidase could open doors to potential therapeutic strategies for treating this disorder and improving patient outcomes.